NO862313D0 - Hybrid-interferoner. - Google Patents

Hybrid-interferoner.

Info

Publication number
NO862313D0
NO862313D0 NO862313A NO862313A NO862313D0 NO 862313 D0 NO862313 D0 NO 862313D0 NO 862313 A NO862313 A NO 862313A NO 862313 A NO862313 A NO 862313A NO 862313 D0 NO862313 D0 NO 862313D0
Authority
NO
Norway
Prior art keywords
interferons
hybrid interferons
novel hybrid
hybrid
interferon
Prior art date
Application number
NO862313A
Other languages
English (en)
Other versions
NO175602B (no
NO862313L (no
NO175602C (no
Inventor
Francois Meyer
Albert Hinnen
Andreas Meister
Markus Gerhard Gruetter
Sefik Alkan
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO862313D0 publication Critical patent/NO862313D0/no
Publication of NO862313L publication Critical patent/NO862313L/no
Publication of NO175602B publication Critical patent/NO175602B/no
Publication of NO175602C publication Critical patent/NO175602C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
NO862313A 1985-06-11 1986-06-10 Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid NO175602C (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides

Publications (4)

Publication Number Publication Date
NO862313D0 true NO862313D0 (no) 1986-06-10
NO862313L NO862313L (no) 1986-12-12
NO175602B NO175602B (no) 1994-07-25
NO175602C NO175602C (no) 1994-11-02

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
NO862313A NO175602C (no) 1985-06-11 1986-06-10 Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid

Country Status (20)

Country Link
US (2) US4885166A (no)
EP (1) EP0205404B1 (no)
JP (2) JPH0655759B2 (no)
KR (1) KR920002267B1 (no)
AT (1) ATE78262T1 (no)
AU (1) AU598196B2 (no)
CA (1) CA1285507C (no)
CY (1) CY1842A (no)
DE (1) DE3685996T2 (no)
DK (1) DK168794B1 (no)
FI (1) FI90983C (no)
GR (1) GR861497B (no)
HK (1) HK99895A (no)
HU (1) HU203255B (no)
IE (1) IE57865B1 (no)
IL (1) IL79085A (no)
NO (1) NO175602C (no)
NZ (1) NZ216485A (no)
PT (1) PT82736B (no)
SG (1) SG25195G (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
EP0546124B2 (en) * 1990-08-29 2003-04-23 Genetics Institute, LLC Multidomain hematopoiesis stimulators
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
EP0548012B1 (en) * 1991-12-16 1997-09-03 Novartis AG Endoplastic reticulum-located recombinant dibasic endoprotease and uses thereof
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0867511A1 (en) * 1992-03-10 1998-09-30 La Jolla Cancer Research Foundation Recombinant calf intestinal alkaline phosphatase
TW218846B (no) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (no) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
ATE207538T1 (de) 1995-02-09 2001-11-15 Behringwerke Ag Verfahren zur produktion von proteinen
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
CN1329082C (zh) 1998-10-16 2007-08-01 拜奥根Idec马萨诸塞公司 干扰素－β－1a的聚合物缀合物及其使用
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
IL155730A0 (en) 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
NZ532779A (en) * 2001-11-09 2008-04-30 Intarcia Therapeutics Inc Method for treating diseases with omega interferon
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2003297285A1 (en) * 2002-11-18 2004-06-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
BRPI0511196A (pt) * 2004-05-19 2007-12-04 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
JP2008509889A (ja) * 2004-06-30 2008-04-03 イージェン コーポレーション ペグ化インターフェロンα−１ｂ
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
PL2634242T3 (pl) 2006-07-14 2017-09-29 Patheon Holdings I B.V. Ulepszony sposób hodowli komórek
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US20100143373A1 (en) 2006-12-06 2010-06-10 Medimmune, Llc Methods of treating systemic lupus erythematosus
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
CA2685596A1 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2008137838A2 (en) 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
JP5767475B2 (ja) 2007-11-05 2015-08-19 メディミューン，エルエルシー 強皮症の治療方法
MX2010008698A (es) 2008-02-08 2010-12-20 Medimmune Llc Marcadores de enfermedad y usos de los mismos.
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
SI2473636T1 (sl) 2009-09-03 2017-04-26 Medlmmune, Llc Diagnostika inteferona tipa 1
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR102050339B1 (ko) 2011-03-15 2019-11-29 바이오젠 엠에이 인코포레이티드 빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US20220162325A1 (en) 2019-02-15 2022-05-26 Astrazeneca Ab Type i interferon-mediated disorders
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72322B (en) * 1980-01-08 1982-09-23 Biogen Nv Process for preparation of recombinant dna molecules and of polipeptides similar to human interferon
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
IT1167610B (it) * 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons

Also Published As

Publication number Publication date
JPS626000A (ja) 1987-01-12
AU5849986A (en) 1986-12-18
NZ216485A (en) 1991-06-25
FI90983B (fi) 1994-01-14
JPH0655759B2 (ja) 1994-07-27
EP0205404A2 (en) 1986-12-17
JPH0736757B2 (ja) 1995-04-26
IE57865B1 (en) 1993-05-05
DE3685996D1 (de) 1992-08-20
NO175602B (no) 1994-07-25
US5071761A (en) 1991-12-10
US4885166A (en) 1989-12-05
SG25195G (en) 1995-08-18
IE861542L (en) 1986-12-11
KR870000427A (ko) 1987-02-18
DE3685996T2 (de) 1993-01-14
AU598196B2 (en) 1990-06-21
EP0205404B1 (en) 1992-07-15
JPH05308973A (ja) 1993-11-22
HUT41846A (en) 1987-05-28
KR920002267B1 (ko) 1992-03-20
IL79085A (en) 1992-03-29
HK99895A (en) 1995-06-30
CA1285507C (en) 1991-07-02
NO862313L (no) 1986-12-12
PT82736B (pt) 1988-12-15
FI862461A0 (fi) 1986-06-09
NO175602C (no) 1994-11-02
ATE78262T1 (de) 1992-08-15
IL79085A0 (en) 1986-09-30
FI862461A (fi) 1986-12-12
DK272986D0 (da) 1986-06-10
EP0205404A3 (en) 1987-10-21
FI90983C (fi) 1994-04-25
CY1842A (en) 1996-03-08
GR861497B (en) 1986-10-10
DK272986A (da) 1986-12-12
PT82736A (en) 1986-07-01
DK168794B1 (da) 1994-06-13
HU203255B (en) 1991-06-28

Similar Documents

Publication Publication Date Title
ATE78262T1 (de) Hybrid-interferone.
DE3684342D1 (de) Ballistisch widerstandsfaehiges zusammengesetztes erzeugnis.
DE3583521D1 (de) Antivirale verbindungen.
IT8124967A0 (it) Interferoni di leucociti umani ibridi.
FI863378A0 (fi) Rengoeringsfoerfarande av interferon.
FI850275L (fi) Nya 6-susbtituerade furo-(3,4-c) -pyridinderivat.
FR2431507A1 (fr) 1-desamino-2-desoxy-2-epi-amino fortimicine b
FI872096A0 (fi) Foerhoejd expression av humant interleukin-2 i daeggdjursceller.
EP0315637A4 (en) POLYPEPTIDES USEFUL IN THE DIAGNOSIS OF MYCOPLASMA INFECTIONS IN PIGS, AND RECOMBINANT DNA METHODS FOR THEIR MANUFACTURE.
DE3577713D1 (de) Thermoplastische, weichmacherhaltige polyvinylbutyralformmassen.
DE3575435D1 (de) Sinterfaehige, feinteilige formmasse auf basis von vinylchlorid-polymerisaten.
NO166727C (no) Fremgangsmaate for fremstilling av rekombinant alfa-interferon
NO894573L (no) Rekombinante interleukin-2 hybridproteiner.
ES8600323A1 (es) Un procedimiento para obtener 2-(2,3,5-tri-o-aril-b-d-ribofuranosil)selenazol-4-carboxilatos de alcohilo o aralcohilo
FI930024A0 (fi) Nya antivirala tetrahydroimidazo(1,4)benzodiazepin-2-(ti)oner
ATA551881A (de) Dreilagiger formkoerper, insbesondere blech, von hoher verschleissfestigkeit
SU939352A1 (ru) Двухмассный вибрационный конвейер
ES2052562T3 (es) Peptido antineoplasico inducido por la interleucina-2.
ATE98263T1 (de) Immunverstaerkung.
LT2393B (lt) Mesos produkto, atgaminancio mesos struktura, gavimo budas

Legal Events

Date Code Title Description
MK1K Patent expired